A detailed review of recent open-label motorsport research on Givaudan's Cereboost, examining its potential effects on mental fatigue and cognitive endurance.
On September 23, 2026, Nutrition Insight reported on new developments surrounding Givaudan’s Cereboost. This specialized ingredient is a standardized American ginseng extract intended for cognitive and mental performance applications. The coverage focused heavily on a 2025 study published in Frontiers in Sports and Active Living, which examined the extract in 58 licensed professional race car drivers using a rigorous simulator environment. Nutrition Insight noted that cognitive health products increasingly target attention and mental energy rather than just traditional sports performance.
The cognitive health sector is actively moving away from simple stimulant formulations. Modern formulations frequently aim to address sustained attention, memory, and cognitive recovery. This shift reflects a growing demand for products that support endurance during demanding mental tasks. Givaudan is positioning Cereboost to meet these specific expectations in the broader market.
The 2025 motorsport trial utilized a specific four phase testing protocol to measure cognitive endurance. Participants began with comprehensive baseline testing to establish their initial driving performance metrics. Researchers then administered a single 200 mg dose of Cereboost to measure immediate acute effects. This initial acute phase was followed by a two week period of daily supplementation at the same 200 mg dose.
Finally, researchers conducted an acute on chronic test to measure cumulative outcomes. This final phase combined the two weeks of daily supplementation with another acute dose taken two hours before testing. The underlying study relied heavily on this baseline comparison model rather than a randomized placebo controlled design. The study targeted experienced professional drivers specifically to ensure baseline stability.
The news coverage indicated that these drivers had already reached a functional learning plateau on the simulator software. Evaluating seasoned professionals helps researchers isolate the specific variable being tested. Researchers intended this selection to reduce the possibility that simple simulator familiarization explained any subsequent performance improvements. The core objective was measuring sustained attention and recovery under simulated demanding conditions.
The protocol tested reaction time, throttle control, and visual coordination during extended periods of focused effort. This approach attempts to quantify mental stamina in a highly controlled, measurable digital environment. The specific combination of acute and chronic dosing phases allowed researchers to observe both immediate and cumulative effects.
David Ferguson is a researcher closely associated with this motorsport study. He stated that supporting cognitive performance could produce relevant athletic performance gains in competitive environments. He also argued that these specific results add to a broader body of clinical research. This body of research attempts to link the ingredient with attention, recovery, mental fatigue, and working memory.
This interpretation is highly commercially relevant to ambitious professionals and operators. The proposed commercial use case focuses on sustained attention under pressure rather than simply providing a temporary stimulant effect. Founders and operators frequently look for reliable methods to maintain focus during long analytical work sessions. A supplement that targets mental fatigue appeals strongly to those managing demanding operational schedules.
For executives, managing energy is not just about staying awake during long hours. It requires preserving the ability to process complex information without degradation late into the evening. However, executives should approach this specific application and its extrapolated claims very thoughtfully. The translation from simulated athletic performance to complex knowledge work is rarely straightforward or guaranteed.
A rigorous racing simulator measures a highly specialized combination of physical reaction time and visuomotor coordination. Those specific physical outcomes are not direct measures of executive decision quality or complex financial analysis capabilities. Evidence for a short term physical change is not equivalent to evidence for better strategic thinking or improved leadership. Leaders interested in strategies for cognitive performance and mental clarity must clearly distinguish between specialized physical testing and actual boardroom output.
Cognitive endurance in a business context relies heavily on emotional regulation, pattern recognition, and sustained executive function.
The study produced distinct sets of objective performance data and subjective participant feedback. During the acute on chronic phase, the reported results included a three second reduction in total lap time. The data also showed faster throttle application in corners during this specific cumulative testing phase. Interestingly, a single acute dose did not improve the fastest lap time or reduce the driving error rate.
The single dose also completely failed to increase the total number of laps completed by the drivers. This lack of acute results suggests the most prominent performance improvement was associated with the cumulative condition. A single isolated dose alone did not drive the primary performance metric for these drivers. The article notably does not provide detailed statistical tables, p-values, or confidence intervals for the reported outcomes.
Without these detailed statistical measures, evaluating the true magnitude of the observed physical changes remains somewhat difficult. The subjective findings relied entirely on participant reported perceptions rather than objective biological markers. According to the news report, 97 percent of the drivers felt their mental acuity improved during the trial. Additionally, 94 percent said the botanical supplement improved their actual driving capabilities.
The article noted that 91 percent of participants felt these improvements quickly after beginning the protocol. Another 77 percent claimed the improvement was faster than with other solutions they had tried previously. ExecuFuel advises treating these specific percentages strictly as subjective perceptions rather than objective proof of workplace productivity.
Rigorous evaluation requires clearly acknowledging the deep structural limitations of this specific research model. The 2025 study was an open label trial and was partly funded by Givaudan. Participants knew exactly what they were taking during the entirety of the experiment. An open label design without a reported placebo group is highly vulnerable to expectancy effects and demand characteristics.
The available coverage does not establish that these specific motorsport findings have been independently reproduced by unaffiliated researchers. Earlier research cited in the coverage includes a 2010 acute randomized double blind placebo controlled crossover study. This earlier study examined American ginseng and neurocognitive function using a much stronger clinical design. However, this older study examined American ginseng generally and cannot automatically be treated as equivalent to the current formulation.
Product specific evidence is absolutely essential when evaluating botanical supplements for professional use. The broader evidence base spans completely different ginseng species, extraction methods, and outcome measures. Differences in extraction methods or testing intervals can materially change the final biological outcome. Broader evidence regarding general ginseng supplementation remains highly heterogeneous across different populations.
A recent evidence review reported that general ginseng research has found small positive effects in some cognitive domains. This review specifically highlighted memory as an area of potential measurable benefit. However, the same review emphasized that studies use different preparations and often measure only short term effects. Furthermore, the evidence remains insufficient to recommend ginseng for preventing cognitive decline or treating mild cognitive impairment.
Givaudan says Health Canada approved claims for a daily 200 mg Cereboost dose. These approved claims relate to attention in healthy individuals, mental fatigue, cognitive function, and working memory. However, the available news coverage presents these statements as claims made by the company. A permitted regulatory health claim generally describes the wording under which a product may be marketed. It should never be presented as absolute proof that every user will experience improved attention or superior work performance.
Executives should regard this specific extract as an evidence informed but still preliminary option for personal experimentation. It should not be viewed as a proven or guaranteed workplace productivity intervention. Corporate wellness programs should certainly not base major procurement decisions solely on a single open label simulator study. Adding untested cognitive supplements to a company initiative is premature without further independent placebo controlled trials in office settings.
A far more defensible corporate approach starts with investing heavily in foundational human performance factors. Organizations must prioritize intelligent workload design, adequate breaks, and solid nutrition before purchasing botanical cognitive aids. Executives facing constant mental fatigue must focus first on prioritizing fundamental recovery protocols. Anyone conducting a personal trial should use a consistent dose and track objective work outcomes over multiple weeks.
Users must strictly avoid treating a reported three second simulator improvement as a guaranteed increase in business output. Those taking medication or managing sustained periods of high stress should consult a qualified clinician before starting any new supplementation routine. Future clinical trials may eventually clarify how specific standardized botanical extracts translate from the racing simulator to the office desk. Until those independent trials are published, operators should interpret supplier funded open label research with healthy professional skepticism.
Stay connected for research and practical guidance on executive performance, energy, focus, sleep, recovery and longevity. Ideas built for people who want to stay sharp, capable and effective for the long run.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
